Case Studies
Real Stories. Real Expertise. Proven Results.
Explore how B Squared has partnered with industry leaders to deliver impactful results in Cell & Gene Therapy. Our case studies illustrate the breadth of our expertise and the tangible outcomes we deliver for clients.
Case Study 1
CMC and Process Development for an Advanced Therapy Client
Client & Context: A leading biotech company specializing in regenerative therapies was developing an innovative cell therapy for eye-related conditions. They needed to optimize a suspension formulation that preserved cell viability while integrating seamlessly with a specialized injection device.
Collaboration & Approach: Working in close partnership with the client, the team focused on advanced formulation strategies, process development, and ongoing coordination with the device manufacturer. Proactive technology scouting further streamlined the manufacturing process and prepared the therapy for clinical-scale production.
Outcome: The combined efforts accelerated progress from preclinical to clinical stages, achieving greater stability, precise delivery, and a robust path to market readiness.
Key Takeaways
- Formulation Optimization
- Supplier Alignment
- Technology Scouting
Case Study 2
Strategic Sourcing and Procurement for a Cell Therapy Platform Developer
Client & Context: A global leader in cell therapy manufacturing technology (IDMO) needed to enhance its procurement and strategic sourcing capabilities to support rapid growth. The goals included building robust supplier relationships, optimizing costs, and ensuring an efficient supply of critical raw materials and capital equipment.
Collaboration & Approach: Working closely with the client, the team introduced category management strategies, advanced procurement processes, and stronger supplier partnerships. Regular Quarterly Business Reviews (QBRs) were established to maintain performance standards and drive continuous improvement.
Outcome: Together, these efforts achieved a significant reduction in procurement costs, improved supplier relationships, and streamlined supply chain operations—positioning the client for scalable growth and a stronger competitive edge in the evolving cell therapy market.
Key Takeaways
- Procurement Reorganization
Implemented a category management approach tailored to rapid growth.
- Supplier Negotiations and QBRs
Secured long-term agreements and built continuous improvement cycles through regular reviews.
- Cost Control and Efficiency
Case Study 3
Ongoing Expert Support for a Private Equity Firm in Biotech Investments
Client & Context: A leading international private equity firm specializing in advanced therapy medicinal products (ATMP), cell, and gene therapies needed ongoing expert guidance to optimize sourcing and technical operations. The firm sought a strategic partner for due diligence, market intelligence, and effective engagement with potential investment targets.
Collaboration & Approach: By offering specialized expertise in cell and gene therapy, the team provided regular support across the investment lifecycle. This included anonymized assessments of target companies’ supply chains, strategic market monitoring, and hands-on consulting during initial discussions with potential investments.
Outcome: Through this ongoing collaboration, the firm gained stronger decision-making capabilities and a more competitive portfolio. Portfolio companies also benefited from streamlined operations, improved sourcing, and scalable growth strategies in the rapidly evolving biotech landscape.
Key Takeaways
- Due Diligence Partner
- Market Intelligence
- Strategic Consulting
Case Study 4
Interim CTO Leadership for a Regenerative Medicine Company
Client & Context: A Paris-based regenerative medicine company specializing in cell-based therapies needed guidance transitioning from R&D to clinical manufacturing. Their critical objectives included scaling their technology platform and refining operational processes to meet clinical-grade standards.
Collaboration & Approach: Working closely with the client, the team provided interim leadership to optimize the technology platform, reorganize technical operations, and implement process improvements. Clear leadership structures were introduced to ensure sustainable progress toward clinical-grade production.
Outcome: The collaboration reduced time-to-clinic, accelerating the move to clinical trials. Organizational and process refinements established a robust platform for continued asset development, positioning the company for both near-term clinical milestones and future commercial success.
Key Takeaways
- Organizational Restructuring
- Process Optimization
- Future-Proofing